A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
14
Issued Date
2023-01-01
Resource Type
eISSN
22962565
Scopus ID
2-s2.0-85164866985
Pubmed ID
37457251
Journal Title
Frontiers in public health
Volume
11
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in public health Vol.11 (2023) , 1071117
Suggested Citation
Ngamprasertchai T., Kositamongkol C., Lawpoolsri S., Rattanaumpawan P., Luvira V., Chongtrakool P., Kaewkungwal J., Chokephaibulkit K., Phisalprapa P. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult. Frontiers in public health Vol.11 (2023) , 1071117. doi:10.3389/fpubh.2023.1071117 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/88090
Title
A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
Author's Affiliation
Other Contributor(s)
Abstract
Introduction: This study aims to assess the economic impact of introducing the 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to Thai older adult aged ≥ 65 years who are healthy or with chronic health conditions and immunocompromised conditions from a societal perspective in order to introduce the vaccine to Thailand's National Immunization Program for the older adult. Methods: A Markov model was adopted to simulate the natural history and economic outcomes of invasive pneumococcal diseases using updated published sources and Thai databases. We reported analyses as incremental cost-effectiveness ratios (ICER) in USD per quality-adjusted life year (QALY) gained. In addition, sensitivity analyses and budget impact analyses were conducted. Results: The base-case analysis of all interventions (no vaccinations [current standard of care in Thailand], PPSV23, and PCV13) showed that PPSV23 was extendedly dominated by PCV13. Among healthy individuals or those with chronic health conditions, ICER for PCV13 was 233.63 USD/QALY; meanwhile, among individuals with immunocompromised conditions, ICER for PCV13 was 627.24 USD/QALY. PCV13 are economical vaccine for all older adult Thai individuals when compared to all interventions. Conclusions: In the context of Thailand, PCV13 is recommended as the best buy and should be primarily prioritized when both costs and benefits are considered. Also, this model will be beneficial to the two-next generation pneumococcal vaccines implementation in Thailand.